TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rakovina Therapeutics Inc ( (TSE:RKV) ) has shared an update.
Rakovina Therapeutics Inc. presented a second scientific abstract at the 2025 Society for Neuro-Oncology Annual Meeting, showcasing progress in their AI-derived PARP-1 inhibitor program. The presentation highlighted the company’s use of AI methods to discover and characterize novel PARP1-selective small-molecule drug candidates with central nervous system penetration capabilities. The data demonstrated the successful synthesis and evaluation of hundreds of compounds, with some showing promising PARP1-selective activity and favorable pharmacokinetic profiles. This progress validates Rakovina’s AI-driven discovery platform and underscores its ongoing efforts in the field of DNA-damage-response therapeutics.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on developing innovative cancer treatments. Utilizing unique technologies for targeting the DNA-damage response, the company employs Artificial Intelligence (AI) through proprietary platforms like Deep-Docking™ and Enki™ to expedite the review and optimization of drug candidates. Rakovina aims to advance its distinctive DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners.
Average Trading Volume: 31,131
Technical Sentiment Signal: Sell
Current Market Cap: C$2.64M
See more data about RKV stock on TipRanks’ Stock Analysis page.